Strattera withdrawal. Strattera withdrawal side effects, Strattera withdrawal warnings, Strattera withdrawal precautions, Strattera withdrawal adverse effects, overdose, withdrawal symptoms and Strattera natural alternatives. Before you begin the spiral down with Strattera, try giving your body what it really wants.

Strattera
(atomoxetine)  

Strattera withdrawal Body

Strattera withdrawal Dry Mouth - The usual amount to moisture in the mouth is noticeably less.

Strattera withdrawal Sweating Increased - A large quantity of perspiration that is medically caused.

Strattera withdrawal Cardiovascular (Involving the heart and the blood vessels)

Strattera withdrawal Palpitation - Unusual and not normal heartbeat, that is sometimes irregular, but rapid and forceful thumping or fluttering.  It can be brought on by shock, excitement, exertion, or medical stimulants.  A person is normally unaware of his/her heartbeat.

Strattera withdrawal Hypertension - is high blood pressure, which is a symptom of disease in the blood vessels leading away from the heart.  Hypertension is known as the “silent killer”.  The symptoms are usually not obvious, however it can lead to damage to the heart, brain, kidneys and eye, and even to stroke and kidney failure. Treatment includes dietary and lifestyle changes.

Strattera withdrawal Bradycardia - The heart rate is slowed from 72 beats per minute, which is normal, to below 60 beats per minute in an adult.

Strattera withdrawal Tachycardia - The heart rate is speeded up to above 100 beats per minute in an adult.  Normal adult heart rate is 72 beats per minute.

Strattera withdrawal ECG Abnormal - A test called an electrocardiogram (ECG) that records the activity of the heart.  It measures heartbeats as will as the position and size of the heart’s four chambers.  It also measures if there is damage to the heart and the effects of drugs or mechanical devices like a pacemaker on the heart.  When the test is abnormal this means that one or more of the following are present: heart disease, defects, beating too fast or too slow, disease of the blood vessels leading from the heart or of the heart valves, and/or a past or about to occur heart attack. 

Strattera withdrawal Flushing - The skin all over the body turns red.

Strattera withdrawal Varicose Vein - Unusually swollen veins near the surface of the skin that sometimes appear twisted and knotted, but always enlarged.  They are called hemorrhoids when they appear around the rectum.  The cause is attributed to hereditary weakness in the veins aggravated by obesity, pregnancy, pressure from standing, aging, etc.  Severe cases may develop swelling in the legs, ankles and feet, eczema and/or ulcers in the affected areas.

Strattera withdrawal Gastrointestinal (Involving the stomach and the intestines)

Strattera withdrawal Abdominal Cramp/Pain - Sudden, severe, uncontrollable and painful shortening and thickening of the muscles in the belly.  The belly includes the stomach as well as the intestines, liver, kidneys, pancreas, spleen, gall bladder, and urinary bladder.

Strattera withdrawal Belching - Noisy release of gas from the stomach through the mouth; a burp.

Strattera withdrawal Bloating - Swelling of the belly caused by excessive intestinal gas.

Strattera withdrawal Constipation - Difficulty in having a bowel movement where the material in the bowels is hard due to a lack of exercise, fluid intake, and roughage in the diet, or due to certain drugs.

Strattera withdrawal Diarrhea - Unusually frequent and excessive, runny bowel movements that may result in severe dehydration and shock. 

Strattera withdrawal Dyspepsia - Indigestion.  This is the discomfort you experience after eating.  It can be heartburn, gas, nausea, a bellyache or bloating.

Strattera withdrawal Flatulence - More gas than normal in the digestive organs.

Strattera withdrawal Gagging - Involuntary choking and/or involuntary throwing up.

Strattera withdrawal Gastritis - A severe irritation of the mucus lining of the stomach either short in duration or lasting for a long period of time.

Strattera withdrawal Gastroenteritis - A condition where the membranes of the stomach and intestines are irritated.

Strattera withdrawal Gastroesophageal Reflux - A continuous state where stomach juices flow back into the throat causing acid indigestion and heartburn and possibly injury to the throat.

Strattera withdrawal Heartburn - A burning pain in the area of the breastbone caused by stomach juices flowing back up into the throat.

Strattera withdrawal Hemorrhoids - Small rounded purplish swollen veins that either bleed, itch or are painful and appear around the anus.

 

Strattera withdrawal Increased Stool frequency - Diarrhea.  

Strattera withdrawal Indigestion - Unable to properly consume and absorb food in the digestive tract causing constipation, nausea, stomach ache, gas, swollen belly, pain and general discomfort or sickness.

Strattera withdrawal Nausea - Stomach irritation with a queasy sensation similar to motion sickness and a feeling that one is going to vomit.

Strattera withdrawal Polyposis Gastric - Tumors that grow on stems in the lining of the stomach, which usually become cancerous.

Strattera withdrawal Swallowing Difficulty - A feeling that food is stuck in the throat or upper chest area and won’t go down, making it difficult to swallow.

Strattera withdrawal Toothache - Pain in a tooth above and below the gum line.

Strattera withdrawal Vomiting - Involuntarily throwing up the contents of the stomach and usually getting a nauseated, sick feeling just prior to doing so.

Strattera withdrawal General

Strattera withdrawal Allergy - The extreme sensitivity of body tissues triggered by substances in the air, drugs, or foods causing a reaction like sneezing, itching, asthma, hay fever, skin rashes, nausea and/or vomiting.

Strattera withdrawal Anaphylaxis - A violent, sudden, and severe drop in blood pressure caused by a re-exposure to a foreign protein or a second dosage of a drug that may be fatal unless emergency treatment is given right away.

Strattera withdrawal Asthenia - A physically weak condition.

Strattera withdrawal Chest Pains - Severe discomfort in the chest caused by not enough oxygen going to the heart because of narrowing of the blood vessels or spasms.

Strattera withdrawal Chills - Appearing pale while cold and shivering; sometimes with a fever.

Strattera withdrawal Edema of Extremities - Abnormal swelling of the body’s tissue caused by the collection of fluid.

Strattera withdrawal Fall - To suddenly lose your normal standing upright position as if you were shot.

Strattera withdrawal Fatigue - Loss of normal strength so as to not be able to do the usual physical and mental activities. 

Strattera withdrawal Fever - Abnormally high body temperature, the normal being 98 degrees Fahrenheit or 37 degrees Centigrade in humans, which is a symptom of disease or disorder in the body.  The body is affected by feeling hot, chilled, sweaty, weak and exhausted.  If the fever goes too high, death can result.

Strattera withdrawal Hot Flashes - Brief, abnormal enlargement of the blood vessels that causes a sudden heat sensation over the entire body.  Women in menopause will sometimes experience this.

Strattera withdrawal Influenza-like Symptoms - Demonstrating irritation of the respiratory tract (organs of breathing) such as a cold, sudden fever, aches and pains, as well as feeling weak and seeking bed rest, which is similar to having the flu.

Strattera withdrawal Leg Pain - A hurtful sensation in the legs that is caused by excessive stimulation of the nerve endings in the legs and results in extreme discomfort.

Strattera withdrawal Malaise - The somewhat unclear feeling of discomfort you get when you start to feel sick.

Strattera withdrawal Pain in Limb - Sudden, sharp and uncontrolled leg discomfort.

Strattera withdrawal Syncope - A short period of light headedness or unconsciousness (black-out) also know as fainting caused by lack of oxygen to the brain because of an interruption in blood flowing to the brain.

Strattera withdrawal Tightness of Chest - Mild or sharp discomfort, tightness or pressure in the chest area (anywhere between the throat and belly).  The causes can be mild or seriously life-threatening because they include the heart, lungs and surrounding muscles.

Strattera withdrawal Hemic and Lymphatic Disorders (Involving the blood and the clear fluids in the tissues that contain white blood cells)

Strattera withdrawal Bruise - Damage to the skin resulting in a purple-green-yellow skin coloration that’s caused by breaking the blood vessels in the area without breaking the surface of the skin.

Strattera withdrawal Anemia - A condition where the blood is no longer carrying enough oxygen, so the person looks pale and easily gets dizzy, weak and tired.  More severely, a person can end up with an abnormal heart, as well as breathing and digestive difficulties.  The causes of anemia are not enough protein in the red blood cells, or missing and chemically destroyed red blood cells, as well as diseased or destroyed bone marrow.

Strattera withdrawal Nosebleed - Blood lost from the part of the face that has the organs of smell and is where the body takes in oxygen.

Strattera withdrawal Hematoma - Broken blood vessels that cause a swelling in an area on the body.

Strattera withdrawal Lymphadenopathy Cervical - The lymph nodes in the neck, which are part of the body’s immune system get swollen and enlarge by reacting to the presence of a drug.  The swelling is the result of the white blood cells multiplying in order to fight the invasion of the drug.

Strattera withdrawal Metabolic and Nutritional Disorders (Energy and health)

Strattera withdrawal Arthralgia - Sudden sharp nerve pain in one or more joints.

Strattera withdrawal Arthropathy - Having joint disease or abnormal joints.

Strattera withdrawal Arthritis - Painfully inflamed and swollen joints.  The reddened and swollen condition is brought on by a serious injury or shock to the body either from physical or emotional causes.

Strattera withdrawal Back Discomfort - Severe physical distress in the area from the neck to the pelvis along the backbone.

Strattera withdrawal Bilirubin Increased - Bilirubin is a waste product of the breakdown of old blood cells.  Bilirubin is sent to the liver to be made water-soluble so it can be eliminated from the body through emptying the bladder.  A drug can interfere with or damage this normal liver function creating liver disease.

Strattera withdrawal Decreased Weight - Uncontrolled and measured loss of heaviness or weight.

Strattera withdrawal Gout - A severe arthritis condition that is caused by the dumping of a waste product called uric acid in the tissues and joints.  It can become worse and cause the body to develop a deformity after going through stages of pain, inflammation, severe tenderness, and stiffness.

Strattera withdrawal Hepatic Enzymes Increased - An increase in the amount of paired liver proteins that regulate liver processes causing a condition where the liver functions abnormally.

Strattera withdrawal Hypercholesterolemia - Too much cholesterol in the blood cells.

Strattera withdrawal Hyperglycemia - An unhealthy amount of sugar in the blood.

Strattera withdrawal Increased Weight - A concentration and storage of fat in the body accumulating over a period of time caused by unhealthy eating patterns, that can predispose the body to many disorders and diseases.

Strattera withdrawal Jaw Pain - The pain due to irritation and swelling of the nerves associated with the mouth area where it opens and closes just in front of the ear.  Some of the symptoms are pain when chewing, head aches, losing your balance, stuffy ears or ringing in the ears, and teeth grinding.

Strattera withdrawal Jaw Stiffness - The result of squeezing and grinding the teeth while asleep that can cause your teeth to deteriorate as well as the muscles and joints of the jaw.

Strattera withdrawal Joint Stiffness - A loss of free motion and easy flexibility where any two bones come together.

Strattera withdrawal Muscle Cramp - When muscles contract uncontrollably without warning and do not relax.  The muscles of any of the body’s organs can cramp.

Strattera withdrawal Muscle Stiffness - Tightening of muscles making it difficult to bend.

Strattera withdrawal Muscle Weakness - Loss of physical strength.

Strattera withdrawal Myalgia - A general widespread pain and tenderness of the muscles.

Strattera withdrawal Thirst - A strong, unnatural craving for moisture/water in the mouth and throat. 

Strattera withdrawal Nervous System (Sensory channels)

Strattera withdrawal Carpal Tunnel Syndrome - A pinched nerve in the wrist that causes pain, tingling, and numbing.

Strattera withdrawal Coordination Abnormal - A lack of normal, harmonious interaction of the parts of the body when it is in motion.

Strattera withdrawal Dizziness - Losing one’s balance while feeling unsteady and lightheaded which may lead to fainting.

Strattera withdrawal Disequilibrium - Lack of mental and emotional balance.

Strattera withdrawal Faintness - A temporary condition where one is likely to go unconscious and fall.

Strattera withdrawal Headache - A sharp or dull persistent pain in the head

Strattera withdrawal Hyperreflexia - A not normal and involuntary increased response in the tissues connecting the bones to the muscles.

Strattera withdrawal Light-headed Feeling – Uncontrolled and usually brief loss of consciousness caused by lack of oxygen to the brain.

Strattera withdrawal Migraine - Reoccurring severe head pain usually with nausea, vomiting, dizziness, flashes or spots before the eyes, and ringing in the ears

Strattera withdrawal Muscle Contractions Involuntary - Spontaneous and uncontrollable tightening reaction of the muscles caused by electrical impulses from the nervous system.

Strattera withdrawal Muscular Tone Increased - Uncontrolled and exaggeration muscle tension.  Muscles are normally partially tensed and this is what gives us muscle tone. 

Strattera withdrawal Paresthesia - Burning, prickly, itchy, or tingling skin with no obvious or understood physical cause.

Strattera withdrawal Restless Legs - A need to move the legs without any apparent reason.  Sometimes there is pain, twitching, jerking, cramping, burning, or a creepy-crawly sensation associated with the movements.  It worsens when a person is inactive and can interrupt one’s sleep so one feels the need to move to gain some relief.

Strattera withdrawal Shaking - Uncontrolled quivering and trembling as if one is cold and chilled.

Strattera withdrawal Sluggishness - Lack of alertness and energy, as well as being slow to respond or perform in life.

Strattera withdrawal Tics - A contraction of a muscle causing a repeated movement not under the control of the person usually on the face or limbs.

Strattera withdrawal Tremor - A nervous and involuntary vibrating or quivering of the body.

Strattera withdrawal Twitching - Sharp, jerky and spastic motion sometimes with a sharp sudden pain.

Strattera withdrawal Vertigo - A sensation of dizziness with disorientation and confusion.

Strattera withdrawal Psychiatric Disorders (Mental and emotional)

Strattera withdrawal Aggravated Nervousness - A progressively worsening, irritated and troubled state of mind.

Strattera withdrawal Agitation - Suddenly violent and forceful, emotionally disturbed state of mind.

Strattera withdrawal Amnesia - Long term or short term, partial or full memory loss created by emotional or physical shock, severe illness, or a blow to the head where the person was caused pain and became unconsciousness.

Strattera withdrawal Anxiety Attack - Sudden and intense feelings of fear, terror, and dread physically creating shortness of breath, sweating, trembling and heart palpitations.

Strattera withdrawal Apathy - Complete lack of concern or interest for things that ordinarily would be regarded as important or would normally cause concern.

Strattera withdrawal Appetite Decreased - Having a lack of appetite despite the ordinary caloric demands of living with a resulting unintentional loss of weight.

Strattera withdrawal Appetite Increased - An unusual hunger causing one to overeat.

Strattera withdrawal Auditory Hallucination - Hearing things without the voices or noises being present.

Strattera withdrawal Bruxism - Grinding and clenching of teeth while sleeping.

Strattera withdrawal Carbohydrate Craving - A drive and craving to eat foods rich in sugar and starches (sweets, snacks and junk foods) that intensifies as the diet becomes more and more unbalanced due to the unbalancing of the proper nutritional requirements of the body.

Strattera withdrawal Concentration Impaired - Unable to easily focus your attention for long periods of time.

Strattera withdrawal Confusion - Not able to think clearly and understand in order to make a logical decision.

Strattera withdrawal Crying Abnormal - Unusual and not normal fits of weeping for short or long periods of time for no apparent reason.

Strattera withdrawal Depersonalization - A condition where one has lost a normal sense of personal identity.

Strattera withdrawal Depression - A hopeless feeling of failure, loss and sadness that can deteriorate into thoughts of death.

Strattera withdrawal Disorientation - A loss of sense of direction, place, time or surroundings as well as mental confusion on personal identity.

Strattera withdrawal Dreaming Abnormal - Dreaming that leaves a very clear, detailed picture and impression when awake that can last for a long period of time and sometimes be unpleasant.

Strattera withdrawal Emotional Lability - Suddenly breaking out in laughter or crying or doing both without being able to control the outburst of emotion.  These episodes are unstable as they are caused by things that normally would not have this effect on an individual.

Strattera withdrawal Excitability - Uncontrollably responding to stimuli.

Strattera withdrawal Feeling Unreal - The awareness that one has an undesirable emotion like fear but can’t seem to shake off the irrational feeling.  For example, feeling like one is going crazy but rationally knowing that it is not true.  The quality of this side effect resembles being in a bad dream and not being able to wake up.

Strattera withdrawal Forgetfulness - Unable to remember what one ordinarily would remember.

Strattera withdrawal Insomnia - Sleeplessness caused by physical stress, mental stress or stimulants such as coffee or medications; it is a condition of being abnormally awake when one would ordinarily be able to fall and remain asleep.

Strattera withdrawal Irritability - Abnormally annoyed in response to a stimulus.

Strattera withdrawal Jitteriness - Nervous fidgeting without an apparent cause.

Strattera withdrawal Lethargy - Mental and physical sluggishness and apathy that can deteriorate into an unconscious state resembling deep sleep.  A numbed state of mind.

Strattera withdrawal Libido Decreased - An abnormal loss of sexual energy or desire.

Strattera withdrawal Panic Reaction - A sudden, overpowering, chaotic and confused mental state of terror resulting in being doubt ridden often accompanied with hyperventilation, and extreme anxiety.

Strattera withdrawal Restlessness Aggravated - A constantly worsening troubled state of mind characterized by the person being increasingly nervous, unable to relax, and easily angered.

Strattera withdrawal Somnolence - Feeling sleepy all the time or having a condition of semi-consciousness.

Strattera withdrawal Suicide Attempt - An unsuccessful deliberate attack on one’s own life with the intention of ending it.

Strattera withdrawal Suicidal Tendency - Most likely will attempt to kill oneself.

Strattera withdrawal Tremulousness Nervous - Very jumpy, shaky, and uneasy while feeling fearful and timid.  The condition is characterized by thoughts of dreading the future, involuntary quivering, trembling, and feeling distressed and suddenly upset.

Strattera withdrawal Yawning - involuntary opening of the mouth with deep inhalation of air.

Strattera withdrawal Reproductive Disorder Female

Strattera withdrawal Breast Neoplasm - A tumor or cancer, of either of the two milk-secreting organs on the chest of a woman. 

Strattera withdrawal Menorrhagia - Abnormally heavy menstrual period or a menstrual flow that has continued for an unusually long period of time.

Strattera withdrawal Menstrual Cramps - Painful, involuntary uterus contractions that women experience around the time of their menstrual period, sometimes causing pain in the lower back and thighs.

Strattera withdrawal Menstrual Disorder - A disturbance or derangement in the normal function of a woman’s menstrual period.

Strattera withdrawal Pelvic Inflammation - The reaction of the body to infectious, allergic, or chemical irritation, which in turn causes tissue irritation, injury, or bacterial infection characterized by pain, redness, swelling, and sometimes loss of function. The reaction usually begins in the uterus and spreads to the fallopian tubes, ovaries, and other areas in the hipbone region of the body.

Strattera withdrawal Premenstrual Syndrome - Various physical and mental symptoms commonly experienced by women of childbearing age usually 2 to 7 days before the start of their monthly period.  There are over 150 symptoms including eating binges, behavioral changes, moodiness, irritability, fatigue, fluid retention, breast tenderness, headaches, bloating, anxiety, and depression.  The symptoms cease shortly after the period begins, and disappear with menopause.

Strattera withdrawal Spotting Between Menses - Abnormal bleeding between periods.  Unusual spotting between menstrual cycles.

Strattera withdrawal RESPIRATORY SYSTEM (Organs involved in breathing)

Strattera withdrawal Asthma - A disease of the breathing system initiated by and allergic reaction or a chemical with repeated attacks of coughing, sticky mucus, wheezing, shortness of breath, and a tight feeling in the chest.  The disease can reach a state where it stops a person from exhaling, leading to unconsciousness and death.

Strattera withdrawal Breath Shortness - Unnatural breathing using a lot off effort resulting in not enough air taken in by the body.

Strattera withdrawal Bronchitis - Inflammation of the two main breathing tubes leading from the windpipe to the lungs.  The disease is marked with coughing, a low-grade fever, chest pains, and hoarseness, caused by an allergic reaction.

Strattera withdrawal Coughing - A cough is the response to an irritation, such as mucus, that causes the muscles controlling the breathing process to expel air from the lungs suddenly and noisily to keep the air passages free from the irritating material.

Strattera withdrawal Laryngitis - Inflammation of the voice box characterized by hoarseness, sore throat, and coughing.  It can be cause by straining the voice or exposure to infectious, allergic or chemical irritation.

Strattera withdrawal Nasal Congestion - The presence of an abnormal amount of fluid in the nose.

Strattera withdrawal Pneumonia Tracheitis - Bacterial infection of the air passageways and lungs that causes redness, swelling and pain in the windpipe.  Other symptoms are high fever, chills, pain in the chest, difficulty in breathing, and coughing with mucus discharge.

Strattera withdrawal Rhinitis - Chemical irritation causing pain, redness and swelling in the mucus membranes of the nose.

Strattera withdrawal Sinus Congestion - The mucus-lined areas of the bones in the face that are thought to help warm and moisten air to the nose.  These areas become clogged with excess fluid or infected.

Strattera withdrawal Sinus Headache - The abnormal amount of fluid in the hollows of the face bone area especially around the nose.  This excess fluid creates pressure, causing pain in the head.

Strattera withdrawal Sinusitis - The body reacting to chemical irritation causing redness, swelling and pain in the area of the hollows in the facial bones especially around the nose.

Strattera withdrawal SKELETAL

Strattera withdrawal Neck/Shoulder Pain - Hurtful sensations of the nerve endings caused by damage to the tissues in the neck and shoulder signaling danger of disease.

Strattera withdrawal SKIN and APPENDAGES DISORDERS (Skin, legs and arms)

Strattera withdrawal Acne - Eruptions of the oils glands of the skin, especially on the face, marked by pimples, blackheads, whiteheads, bumps, and more severely, by cysts and scarring.

Strattera withdrawal Alopecia - The loss of hair or baldness.

Strattera withdrawal Eczema - A severe or continuing skin disease marked by redness, crusting and scaling with watery blisters and itching.  It is often difficult to treat and will sometimes go away only to reappear again.

Strattera withdrawal Dermatitis - Generally irritated skin that can be caused by any of a number of irritating things such as parasites, fungus, bacteria, or foreign substances causing an allergic reaction.  It is a general inflammation of the skin.

Strattera withdrawal Dry Lips - The lack of normal moisture in the fleshy folds that surround the mouth.

Strattera withdrawal Dry Skin - The lack of normal moisture/oils in the surface layer of the body.  The skin is the body’s largest organ.

 

Strattera withdrawal Folliculitis - Inflammation of a follicle (small body sac) especially a hair follicle.  A hair follicle contains the root of a hair.

 

Strattera withdrawal Furunculosis - Skin boils that show up repeatedly.

 

Strattera withdrawal Lipoma - A tumor of mostly fat cells that is not health endangering.

 

Strattera withdrawal Pruritus - Extreme itching of often-undamaged skin.

 

Strattera withdrawal Rash - A skin eruption or discoloration that may or may not be itching, tingling, burning, or painful.  It may be caused by an allergy, an skin irritation, a skin disease.

 

Strattera withdrawal Skin Nodule - A bulge, knob, swelling or outgrowth in the skin that is a mass of tissue or cells.

 

Strattera withdrawal SPECIAL SENSES

 

Strattera withdrawal Conjunctivitis - Infection of the membrane that covers the eyeball and lines the eyelid, caused by a virus, allergic reaction, or an irritating chemical.  It is characterized by redness, a discharge of fluid and itching.

 

Strattera withdrawal Dry Eyes - Not enough moisture in the eyes.

 

Strattera withdrawal Earache - Pain in the ear.

           

Strattera withdrawal Eye Infection - The invasion of the eye tissue by a bacteria, virus, fungus, etc, causing damage to the tissue, with toxicity.  Infection spreading in the body progresses into disease.

 

Strattera withdrawal Eye Irritation - An inflammation of the eye.

 

Strattera withdrawal Metallic Taste - A range of taste impairment from distorted taste to a complete loss of taste.

 

Strattera withdrawal Pupils Dilated - Abnormal expansion of the blace circular opening in the center of the eye.

 

Strattera withdrawal Taste alteration - Abnormal flavor detection in food.

 

Strattera withdrawal Tinnitus - A buzzing, ringing, or whistling sound in one or both ears occurring from the internal use of certain drugs.

 

Strattera withdrawal Vision Abnormal - Normal images are seen differently by the viewer.

 

Strattera withdrawal Vision Blurred - Eyesight is dim or indistinct and hazy in outline or appearance.

 

Strattera withdrawal Visual Disturbance - Eyesight is interfered with or interrupted.  Some disturbances are light sensitivity and the inability to easily distinguish colors.

Strattera withdrawal URINARY SYSTEM DISORDER

Strattera withdrawal Blood in Urine - Blood is present when one empties liquid waste product of the kidneys through the bladder by urinating in the toilet turning the water pink to bright red.  Or you could see pots of blood in the water after urinating. 

Strattera withdrawal Dysuria - Difficult or painful urination.

Strattera withdrawal Kidney Stone - Small hard masses of salt deposits that the kidney forms.

Strattera withdrawal Urinary Frequency - Having to urinate more often than usual or between unusually short time periods.

Strattera withdrawal Urinary Tract Infection - An invasion of bacteria, viruses, fungi, etc., of the system in the body that starts with the kidneys and eliminates urine from the body.  If the invasion goes unchecked it can injure tissue and progress into disease.

Strattera withdrawal Urinary Urgency - A sudden compelling urge to urinate, accompanied by discomfort in the bladder.

Strattera withdrawal UROGENITAL (Urinary tract and genital structures or functions)

Strattera withdrawal Anorgasmia - Failure to experience an orgasm.

Strattera withdrawal Ejaculation Disorder - Dysfunction of the discharge of semen during orgasm.

Strattera withdrawal Menstrual Disorder - Dysfunction of the discharge during the monthly menstrual cycle.

Strattera withdrawal Acute Renal Failure - The kidneys stop functioning properly to excrete wastes.
 

Strattera withdrawal Angioedema - Intensely itching and swelling welts on the skin called hives caused by an allergic reaction to internal or external agents.  The reaction is common to a food or a drug. Chronic cases can last for a long period of time. 

Strattera withdrawal Toxic Epidermal Necrolysis - An abnormal condition where a large portion of skin becomes intensely red and peels off like a second-degree burn.  Often the symptoms include blistering.

Strattera withdrawal Gastrointestinal Hemorrhage - Stomach and intestinal excessive internal bleeding.

Strattera withdrawal Grand Mal Seizures (or Convulsions) - A recurring sudden violent and involuntary attack of muscle spasms with a loss of consciousness.

Strattera withdrawal Neuroleptic Malignant Syndrome - A life threatening, rare reaction to an anti-psychotic drug marked by fever, muscular rigidity, changed mental status, and dysfunction of the autonomic nervous system.

 

Strattera withdrawal Pancreatitis - Chemical irritation with redness, swelling, and pain in the pancreas where digestive enzymes and hormones are secreted.

 

Strattera withdrawal QT Prolongation - A very fast heart rhythm disturbance that is too fast for the heart to beat effectively so the blood to the brain falls causing a sudden loss of consciousness and may cause sudden cardiac death.

 

Strattera withdrawal Rhabdomyolysis - The breakdown of muscle fibers that releases the fibers into the circulatory system.  Some of the fibers are poisonous to the kidney and frequently result in kidney damage.

 

Strattera withdrawal Serotonin Syndrome - A disorder brought on by excessive levels of serotonin caused by drugs and can be fatal as death from this side effect can come very rapidly.

 

Strattera withdrawal Thrombocytopenia - An abnormal decrease in the number of blood platelets in the circulatory system. A decrease in platelets would cause a decrease in the ability of the blood to clot when necessary.

 

Strattera withdrawal Torsades de Pointes - Unusual rapid heart rhythm starting in the lower heart chambers.  If the short bursts of rapid heart rhythm continue for a prolonged period it can degenerate into a more rapid rhythm and can be fatal.

 Strattera withdrawal. How to avoid Strattera withdrawal side effects click here

FDA Talk Paper
T04-60
December 17, 2004       Media Inquiries: 301-827-6242
Consumer Inquiries: 888-INFO-FDA       
New Warning for Strattera
The Food and Drug Administration (FDA) is advising health care professionals about a new warning for Strattera, a drug approved for attention deficit hyperactivity disorder (ADHD) in adults and children. The labeling is being updated with a bolded warning about the potential for severe liver injury following two reports (a teenager and an adult) in patients who had been treated with Strattera for several months, both of whom recovered.

The labeling warns that severe liver injury may progress to liver failure resulting in death or the need for a liver transplant in a small percentage of patients. The labeling also notes that the number of actual cases of severe liver injury is unknown because of under-reporting of post-marketing adverse events.

The bolded warning indicates that the medication should be discontinued in patients who developed jaundice (yellowing of the skin or whites of the eyes) or laboratory evidence of liver injury.

Strattera has been on the market since 2002 and has been used in more than 2 million patients. In clinical trials of 6000 patients, no signal for liver problems (hepatotoxicity) had emerged.

FDA has asked the manufacturer to add a bolded warning about severe liver injury to the labeling. Eli Lilly has agreed to alert health care professionals about the new information in a Dear Health Professional letter. The company will also update the patient package insert with information about the signs and symptoms of liver problems, which include:

• Pruritus (Itchy skin)
• Jaundice
• Dark urine
• Upper right-sided abdominal tenderness
• Or unexplained “flu-like” symptoms

Health care professionals are encouraged to report any unexpected adverse events associated with Strattera directly to Eli Lilly, Indianapolis, Ind., at 1800-LillyRx or to the FDA MedWatch program at 1800-FDA-1088. The MedWatch form is available online at http://www.fda.gov/medwatch/safety/3500.pdf for download by mail (or fax, 1800-FDA-0178) to MedWatch, HFD-410, FDA, 5600 Fishers Lane, Rockville, Md. 20857.

Strattera is really an antidepressant that Eli Lilly could not find a market for in the early 1990's. Eli Lilly sat on the drug until they came up with the idea of using it for ADHD. If you are giving Strattera to your child or thinking about doing so, know you are really giving them an antidepressant and all caution should be taken.

Before allowing your child to take Strattera, please read down this page and pay special note to the bold text. We know most parents would not give their child medication if they knew it would cause more harm than good. We also understand the need for a parent to receive verifiable information that is also reliable.

The Strattera information below is from the Physicians' Desk Reference, supplied by Eli Lilly. Their report, not ours. We are only evaluating their data. 

At issue with Strattera as well as with the class of antidepressants called SSRIs, is the metabolism and side effects.

Eli Lilly Employees - It is time for you to come clean like many of the FDA scientist have done over the past month. Children are the future of our civilization and you are killing them. You can send me an e-mail that will be held in confidence if you wish. Click here

STRATTERA™ (Lilly)
(atomoxetine HCl)

DESCRIPTION

STRATTERA™ (atomoxetine HCl) is a selective norepinephrine reuptake inhibitor. Atomoxetine HCl is the R (-) isomer as determined by x-ray diffraction. The chemical designation is (-)- N -methyl-3-phenyl-3-( o -tolyloxy)-propylamine hydrochloride. The molecular formula is C ₁₇ H ₂₁ NO•HCl, which corresponds to a molecular weight of 291.82.

CLINICAL PHARMACOLOGY

Pharmacodynamics and Mechanism of Action

The precise mechanism by which atomoxetine produces its therapeutic effects in Attention-Deficit/Hyperactivity Disorder (ADHD) is unknown, but is thought to be related to selective inhibition of the pre-synaptic norepinephrine transporter, as determined in ex vivo uptake and neurotransmitter depletion studies. (Editors note - Eli Lilly admits upfront this is guess work)

Back to top of page   Metabolism Test

Human Pharmacokinetics

Atomoxetine is well-absorbed after oral administration and is minimally affected by food. It is eliminated primarily by oxidative metabolism through the cytochrome P450 2D6 (CYP2D6) enzymatic pathway and subsequent glucuronidation. Atomoxetine has a half-life of about 5 hours. A fraction of the population (about 7% of Caucasians and 2% of African Americans) are poor metabolizers (PMs) of CYP2D6 metabolized drugs. These individuals have reduced activity in this pathway resulting in 10-fold higher AUCs, 5-fold higher peak plasma concentrations, and slower elimination (plasma half-life of about 24 hours) of atomoxetine compared with people with normal activity [extensive metabolizers (EMs)]. Drugs that inhibit CYP2D6, such as fluoxetine, paroxetine, and quinidine, cause similar increases in exposure. (Editors note - If your child is a poor metabolizer, the half life or how long the drug stays in the system is 10 fold that of normal metabolizer plus the peak concentration of Strattera is 5 fold higher)

The pharmacokinetics of atomoxetine have been evaluated in more than 400 children and adolescents in selected clinical trials, primarily using population pharmacokinetic studies. Single-dose and steady-state individual pharmacokinetic data were also obtained in children, adolescents, and adults. When doses were normalized to a mg/kg basis, similar half-life, C _max , and AUC values were observed in children, adolescents, and adults. Clearance and volume of distribution after adjustment for body weight were also similar.

Back to top of page   Metabolism Test

Absorption and Distribution --Atomoxetine is rapidly absorbed after oral administration, with absolute bioavailability of about 63% in EMs and 94% in PMs. Maximal plasma concentrations (C _max ) are reached approximately 1 to 2 hours after dosing.

Metabolism and Elimination --Atomoxetine is metabolized primarily through the CYP2D6 enzymatic pathway. People with reduced activity in this pathway (PMs) have higher plasma concentrations of atomoxetine compared with people with normal activity (EMs). For PMs, AUC of atomoxetine is approximately 10-fold and C _ss,max is about 5-fold greater than EMs. Laboratory tests are available to identify CYP2D6 PMs. Coadministration of STRATTERA with potent inhibitors of CYP2D6, such as fluoxetine, paroxetine, or quinidine, results in a substantial increase in atomoxetine plasma exposure, and dosing adjustment may be necessary. Atomoxetine did not inhibit or induce the CYP2D6 pathway. (Editors note - Eli Lilly finally is admitting there is a test that can determine this)

Back to top of page   Metabolism Test

The major oxidative metabolite formed, regardless of CYP2D6 status, is 4-hydroxyatomoxetine, which is glucuronidated. 4-Hydroxyatomoxetine is equipotent to atomoxetine as an inhibitor of the norepinephrine transporter but circulates in plasma at much lower concentrations (1% of atomoxetine concentration in EMs and 0.1% of atomoxetine concentration in PMs). 4-Hydroxyatomoxetine is primarily formed by CYP2D6, but in PMs, 4-hydroxyatomoxetine is formed at a slower rate by several other cytochrome P450 enzymes. N-Desmethylatomoxetine is formed by CYP2C19 and other cytochrome P450 enzymes, but has substantially less pharmacological activity compared with atomoxetine and circulates in plasma at lower concentrations (5% of atomoxetine concentration in EMs and 45% of atomoxetine concentration in PMs).

Mean apparent plasma clearance of atomoxetine after oral administration in adult EMs is 0.35 L/hr/kg and the mean half-life is 5.2 hours. Following oral administration of atomoxetine to PMs, mean apparent plasma clearance is 0.03 L/hr/kg and mean half-life is 21.6 hours. For PMs, AUC of atomoxetine is approximately 10-fold and C _ss,max is about 5-fold greater than EMs. The elimination half-life of 4-hydroxyatomoxetine is similar to that of N-desmethylatomoxetine (6 to 8 hours) in EM subjects, while the half-life of N-desmethylatomoxetine is much longer in PM subjects (34 to 40 hours). (Editors note - The difference here in half life for poor metabolizer is 34-40 hours vs. 6-8 hours. We are talking days difference. If you are still taking Strattera on top of this, imagine what is happening inside the body)

Back to top of page   Metabolism Test

Atomoxetine is excreted primarily as 4-hydroxyatomoxetine- O -glucuronide, mainly in the urine (greater than 80% of the dose) and to a lesser extent in the feces (less than 17% of the dose). Only a small fraction of the STRATTERA dose is excreted as unchanged atomoxetine (less than 3% of the dose), indicating extensive biotransformation.

Drug-Drug Interactions

CYP2D6 activity and atomoxetine plasma concentration --Atomoxetine is primarily metabolized by the CYP2D6 pathway to 4-hydroxyatomoxetine. In EMs, inhibitors of CYP2D6 increase atomoxetine steady-state plasma concentrations to exposures similar to those observed in PMs. Dosage adjustment of STRATTERA in EMs may be necessary when coadministered with CYP2D6 inhibitors, e.g., paroxetine, fluoxetine, and quinidine. In vitro studies suggest that coadministration of cytochrome P450 inhibitors to PMs will not increase the plasma concentrations of atomoxetine.

Effect of atomoxetine on P450 enzymes --Atomoxetine did not cause clinically important inhibition or induction of cytochrome P450 enzymes, including CYP1A2, CYP3A, CYP2D6, and CYP2C9.

Albuterol --Albuterol (600 mcg iv over 2 hours) induced increases in heart rate and blood pressure. These effects were potentiated by atomoxetine (60 mg BID for 5 days) and were most marked after the initial coadministration of albuterol and atomoxetine.

Back to top of page   Metabolism Test

Alcohol --Consumption of ethanol with STRATTERA did not change the intoxicating effects of ethanol.

Desipramine --Coadministration of STRATTERA (40 or 60 mg BID for 13 days) with desipramine, a model compound for CYP2D6 metabolized drugs (single dose of 50 mg), did not alter the pharmacokinetics of desipramine. No dose adjustment is recommended for drugs metabolized by CYP2D6.

Methylphenidate --Coadministration of methylphenidate with STRATTERA did not increase cardiovascular effects beyond those seen with methylphenidate alone.

Midazolam --Coadministration of STRATTERA (60 mg BID for 12 days) with midazolam, a model compound for CYP3A4 metabolized drugs, (single dose of 5 mg), resulted in 15% increase in AUC of midazolam. No dose adjustment is recommended for drugs metabolized by CYP3A.

Back to top of page   Metabolism Test

Precautions

In pediatric placebo-controlled trials, STRATTERA-treated subjects experienced a mean increase in heart rate of about 6 beats/minute compared with placebo subjects. At the final study visit before drug discontinuation, 3.6% (12/335) of STRATTERA-treated subjects had heart rate increases of at least 25 beats/minute and a heart rate of at least 110 beats/minute, compared with 0.5% (1/204) of placebo subjects. No pediatric subject had a heart rate increase of at least 25 beats/minute and a heart rate of at least 110 beats/minute on more than one occasion. Tachycardia was identified as an adverse event for 1.5% (5/340) of these pediatric subjects compared with 0.5% (1/207) of placebo subjects. The mean heart rate increase in extensive metabolizer (EM) patients was 6.7 beats/minute, and in poor metabolizer (PM) patients 10.4 beats/minute.

Back to top of page   Metabolism Test

Laboratory Tests

Routine laboratory tests are not required.

CYP2D6 metabolism --Poor metabolizers (PMs) of CYP2D6 have a 10-fold higher AUC and a 5-fold higher peak concentration to a given dose of STRATTERA compared with extensive metabolizers (EMs). Approximately 7% of a Caucasian population are PMs. Laboratory tests are available to identify CYP2D6 PMs. The blood levels in PMs are similar to those attained by taking strong inhibitors of CYP2D6. The higher blood levels in PMs lead to a higher rate of some adverse effects of STRATTERA. (Eli Lilly admits a higher rate of adverse reaction if you are a poor metabolizer)

Back to top of page   Metabolism Test

CYP2D6 inhibitors --Atomoxetine is primarily metabolized by the CYP2D6 pathway to 4-hydroxyatomoxetine. In EMs, selective inhibitors of CYP2D6 increase atomoxetine steady-state plasma concentrations to exposures similar to those observed in PMs. Dosage adjustment of STRATTERA may be necessary when coadministered with CYP2D6 inhibitors, e.g., paroxetine, fluoxetine, and quinidine. In EM individuals treated with paroxetine or fluoxetine, the AUC of atomoxetine is approximately 6- to 8-fold and C _ss,max is about 3- to 4-fold greater than atomoxetine alone.

Child and Adolescent Clinical Trials

Reasons for discontinuation of treatment due to adverse events in child and adolescent clinical trials --In acute child and adolescent placebo-controlled trials, 3.5% (15/427) of atomoxetine subjects and 1.4% (4/294) placebo subjects discontinued for adverse events. For all studies, (including open-label and long-term studies), 5% of extensive metabolizer (EM) patients and 7% of poor metabolizer (PM) patients discontinued because of an adverse event. Among STRATTERA-treated patients, aggression (0.5%, N=2); irritability (0.5%, N=2); somnolence (0.5%, N=2); and vomiting (0.5%, N=2) were the reasons for discontinuation reported by more than 1 patient.

Back to top of page   Metabolism Test

The following adverse events occurred in at least 2% of PM patients and were either twice as frequent or statistically significantly more frequent in PM patients compared with EM patients: decreased appetite (23% of PMs, 16% of EMs); insomnia (13% of PMs, 7% of EMs); sedation (4% of PMs, 2% of EMs); depression (6% of PMs, 2% of EMs); tremor (4% of PMs, 1% of EMs); early morning awakening (3% of PMs, 1% of EMs); pruritus (2% of PMs, 1% of EMs); mydriasis (2% of PMs, 1% of EMs).

Back to top of page   Metabolism Test

General Dosing Information

STRATTERA may be taken with or without food.

The safety of single doses over 120 mg and total daily doses above 150 mg have not been systematically evaluated.

Dosing adjustment for hepatically impaired patients --For those ADHD patients who have hepatic insufficiency (HI), dosage adjustment is recommended as follows: For patients with moderate HI (Child-Pugh Class B), initial and target doses should be reduced to 50% of the normal dose (for patients without HI). For patients with severe HI (Child-Pugh Class C), initial dose and target doses should be reduced to 25% of normal. 

Dosing adjustment for use with a strong CYP2D6 inhibitor --In children and adolescents up to 70 kg body weight administered strong CYP2D6 inhibitors, e.g., paroxetine, fluoxetine, and quinidine, STRATTERA should be initiated at 0.5 mg/kg/day and only increased to the usual target dose of 1.2 mg/kg/day if symptoms fail to improve after 4 weeks and the initial dose is well tolerated.

In children and adolescents over 70 kg body weight and adults administered strong CYP2D6 inhibitors, e.g., paroxetine, fluoxetine, and quinidine, STRATTERA should be initiated at 40 mg/day and only increased to the usual target dose of 80 mg/day if symptoms fail to improve after 4 weeks and the initial dose is well tolerated.